Spago Nanomedical Investor Relations Material
Latest events
Q2 2025
20 Aug, 2025
Q1 2025
7 May, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Spago Nanomedical
Access all reports
Spago Nanomedical AB is a Swedish biotechnology company that specializes in nanomedicine for cancer diagnostics and treatment. The company is advancing two main projects: SpagoPix and Tumorad. SpagoPix is an MRI contrast agent under clinical development, aimed at improving cancer diagnostics by selectively enhancing tumor visibility in breast, liver, and pancreatic cancers. Tumorad is a radionuclide therapy that targets cancer cells using nanoparticles, currently in preclinical stages for treating advanced cancers. Spago Nanomedical is based in Lund, Sweden, and its shares are listed on the Stockholm Stock Exchange.
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
SPAGO
Country
🇸🇪 Sweden